Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $10.9000 (0.32%) ($10.9000 - $10.9000) on Wed. Oct. 11, 2023. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.86% (three month average) | RSI | 38 | Latest Price | $10.9000(0.32%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD advances 0.2% a day on average for past five trading days. | Weekly Trend | FOLD declines -5.5% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) XBI(75%) IBB(69%) ARKG(63%) IWO(56%) JNK(55%) | Factors Impacting FOLD price | FOLD will decline at least -1.43% in a week (0% probabilities). TBT(-41%) UUP(-23%) VXX(-16%) VIXM(-7%) DRIV(1%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.43% (StdDev 2.86%) | Hourly BBV | -0.2 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-2.11(-119.36%) | Resistance Level | $11.82 | 5 Day Moving Average | $10.97(-0.64%) | 10 Day Moving Average | $11.14(-2.15%) | 20 Day Moving Average | $11.82(-7.78%) | To recent high | -20.9% | To recent low | 0.9% | Market Cap | $2.815b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |